Suzhou Transcenta Therapeutics Co., Ltd.

Clinical trials sponsored by Suzhou Transcenta Therapeutics Co., Ltd., explained in plain language.

Now part of Transcenta Holding Limited 6628 HKEX

Biopharmaceutical company developing antibody-based therapies for cancer and other diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1 Not yet recruiting 1 Not yet finished but already full! 2

New triple therapy could extend lives in stomach cancer

Disease control Not yet recruiting

This study tests a new drug called TST001 added to standard chemotherapy and immunotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination helps control the tumor longer and improves surv…

Phase 3 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 08:04 UTC

Suzhou Transcenta Therapeutics Co., Ltd.

New triple therapy could extend lives in stomach cancer